Arrowhead Targets U.S. REDEMPLO Launch for Q2 2027, Subject to FDA Approval

The company reiterated a $3 billion to $4 billion U.S. sales opportunity and said it is too early to provide sales guidance.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.